Nf1 Haploinsufficiency Alters Myeloid Lineage Commitment and Function, Leading to Deranged Skeletal Homeostasis

Although nullizygous loss of NF1 leads to myeloid malignancies, haploinsufficient loss of NF1 (Nf1) has been shown to contribute to osteopenia and osteoporosis which occurs in approximately 50% of neurofibromatosis type 1 (NF1) patients. Bone marrow mononuclear cells of haploinsufficient NF1 patients and Nf1+/– mice exhibit increased osteoclastogenesis and accelerated bone turnover; however, the culprit hematopoietic lineages responsible for perpetuating these osteolytic manifestations have yet to be elucidated. Here we demonstrate that conditional inactivation of a single Nf1 allele within the myeloid progenitor cell population (Nf1‐LysM) is necessary and sufficient to promote multiple osteoclast gains‐in‐function, resulting in enhanced osteoclastogenesis and accelerated osteoclast bone lytic activity in response to proresorptive challenge in vivo. Surprisingly, mice conditionally Nf1 heterozygous in mature, terminally differentiated osteoclasts (Nf1‐Ctsk) do not exhibit any of these skeletal phenotypes, indicating a critical requirement for Nf1 haploinsufficiency at a more primitive/progenitor stage of myeloid development in perpetuating osteolytic activity. We further identified p21Ras‐dependent hyperphosphorylation of Pu.1 within the nucleus of Nf1 haploinsufficient myelomonocytic osteoclast precursors, providing a novel therapeutic target for the potential treatment of NF1 associated osteolytic manifestations. © 2015 American Society for Bone and Mineral Research

[1]  M. Klemsz,et al.  Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. , 1993, Blood.

[2]  M. Klemsz,et al.  Effect of PU.1 phosphorylation on interaction with NF-EM5 and transcriptional activation. , 1993, Science.

[3]  N. Eskiyurt,et al.  Bone mineral density in children with neurofibromatosis 1 , 2007, Acta paediatrica.

[4]  Menggang Yu,et al.  Ras Dependent Paracrine Secretion of Osteopontin by Nf1+/− Osteoblasts Promote Osteoclast Activation in a Neurofibromatosis Type I Murine Model , 2009, Pediatric Research.

[5]  C. Der,et al.  Peptides containing a consensus Ras binding sequence from Raf-1 and theGTPase activating protein NF1 inhibit Ras function. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Cassady,et al.  Transgenic mice that express Cre recombinase in osteoclasts , 2004, Genesis.

[7]  E. Flory,et al.  PKCδ‐Induced PU.1 Phosphorylation Promotes Hematopoietic Stem Cell Differentiation to Dendritic Cells , 2011, Stem cells.

[8]  T. Kuorilehto,et al.  Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. , 2010, Bone.

[9]  E. Sitnicka,et al.  Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow , 2012, The Journal of experimental medicine.

[10]  S. Shapiro,et al.  Osteoclasts are important for bone angiogenesis. , 2010, Blood.

[11]  J. Carey,et al.  Bone mineral density in children and adolescents with neurofibromatosis type 1. , 2007, The Journal of pediatrics.

[12]  A. Robling,et al.  Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. , 2007, Human molecular genetics.

[13]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[14]  D. Largaespada,et al.  Nf1 deficiency causes Ras-Dediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia , 1996, Nature Genetics.

[15]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[16]  Q. Guo,et al.  Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? , 2013, Journal of Translational Medicine.

[17]  K. Mohammad,et al.  Hyperactive Transforming Growth Factor‐β1 Signaling Potentiates Skeletal Defects in a Neurofibromatosis Type 1 Mouse Model , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  J. Tolar,et al.  Osteopetrosis. , 2004, The New England journal of medicine.

[19]  M. Frech,et al.  Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding , 2012, Leukemia.

[20]  E. Jokinen,et al.  A controlled register‐based study of 460 neurofibromatosis 1 patients: Increased fracture risk in children and adults over 41 years of age , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  D. Tenen,et al.  Inhibition of hematopoiesis by competitive binding of transcription factor PU.1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Miller,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .

[23]  J. Marth,et al.  Ablation of NF1 function in neurons induces abnormal development of cerebral cortex and reactive gliosis in the brain. , 2001, Genes & development.

[24]  R. Bloigu,et al.  Decreased bone mineral density and content in neurofibromatosis type 1: Lowest local values are located in the load-carrying parts of the body , 2005, Osteoporosis International.

[25]  J.,et al.  The New England Journal of Medicine , 2012 .

[26]  J. Devente,et al.  Phorbol ester-stimulated phosphorylation of PU.1: association with leukemic cell growth inhibition. , 1996, Blood.

[27]  A. Paller Neurofibromatosis: Phenotype, Natural History, and Pathogenesis , 1993 .

[28]  V. Riccardi,et al.  Neurofibromatosis: Phenotype, Natural History and Pathogenesis , 1993 .

[29]  E. Everett,et al.  Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. , 2005, Bone.

[30]  J. Carey,et al.  Multiple increased osteoclast functions in individuals with neurofibromatosis type 1 , 2011, American journal of medical genetics. Part A.

[31]  D. Ron,et al.  ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. , 2006, Cell metabolism.

[32]  D. Kufe,et al.  Expression of the c-fms proto-oncogene during human monocytic differentiation , 1985, Nature.

[33]  A. Robling,et al.  Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. , 2006, The Journal of clinical investigation.

[34]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Jacks,et al.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells , 1996, Nature Genetics.

[36]  J. Dubousset,et al.  Decreased Bone Mineral Density in Neurofibromatosis-1 Patients with Spinal Deformities , 2001, Osteoporosis International.

[37]  S. Peltonen,et al.  Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro. , 2012, Bone.

[38]  S. Marks,et al.  Congenitally osteopetrotic (oplop) mice are not cured by transplants of spleen or bone marrow cells from normal littermates. , 1984, Metabolic bone disease & related research.

[39]  F. Moreau-Gachelin,et al.  Inhibition of Friend cells proliferation by spi-1 antisense oligodeoxynucleotides. , 1994, Oncogene.

[40]  G. Hutchins,et al.  Nf1-Dependent Tumors Require a Microenvironment Containing Nf1 +/−- and c-kit-Dependent Bone Marrow , 2008, Cell.

[41]  A. Robling,et al.  Erratum: Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1 (Human Molecular Genetics (2008) vol. 17(7) (936-948) 10.1093/hmg/ddm366) , 2008 .

[42]  W. Reith,et al.  Conditional gene targeting in macrophages and granulocytes using LysMcre mice , 1999, Transgenic Research.

[43]  S. Mckercher,et al.  Osteopetrosis in mice lacking haematopoietic transcription factor PU.1 , 1997, Nature.

[44]  Matthew J. Silva,et al.  SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts , 2002, Nature Medicine.

[45]  M. Rouleau,et al.  Roles of osteoclasts in the control of medullary hematopoietic niches. , 2014, Archives of biochemistry and biophysics.

[46]  C. Cowell,et al.  Decreased Bone Mineral Density in Neurofibromatosis Type 1: Results From a Pediatric Cohort , 2007, Journal of pediatric orthopedics.

[47]  S. Peltonen,et al.  Phenotypic characterization of transgenic mice harboring Nf1+/− or Nf1−/− osteoclasts in otherwise Nf1+/+ background , 2012, Journal of cellular biochemistry.

[48]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[49]  R. Friedrich,et al.  Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1) , 2008, Journal of Medical Genetics.

[50]  M. Frech,et al.  Direct interaction of PU.1 with oncogenic transcription factors reduces its serine phosphorylation and promoter binding , 2012, Leukemia.

[51]  J. Lloyd,et al.  Osteopetrosis , 1972 .

[52]  S. Nishikawa,et al.  The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene , 1990, Nature.

[53]  G D Roodman,et al.  Cell biology of the osteoclast. , 1999, Experimental hematology.

[54]  G. Bollag,et al.  Neurofibromin GTPase-activating Protein-related Domains Restore Normal Growth in Nf1−/− Cells* , 2001, The Journal of Biological Chemistry.

[55]  A. Robling,et al.  The Haploinsufficient Hematopoietic Microenvironment Is Critical to the Pathological Fracture Repair in Murine Models of Neurofibromatosis Type 1 , 2011, PloS one.

[56]  E. Scott,et al.  Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. , 1994, Science.

[57]  S. Peltonen,et al.  Follow-Up of Six Patients with Neurofibromatosis 1-Related Osteoporosis Treated with Alendronate for 23 Months , 2014, Calcified Tissue International.

[58]  S. Störkel,et al.  Decreased bone mineral density in patients with neurofibromatosis 1 , 2005, Osteoporosis International.